VERAXA Biotech (NASDAQ: VRXA) Builds Antibody-Based Cancer Pipeline Around Dual-Targeting Precision Investor Brand Network

VERAXA Biotech is changing how antibody-based therapies recognize and attack cancer cells, developing antibody-based cancer therapies with an emphasis on bispecific antibody-drug conjugates (“ADCs”) and T-cell engagers (“TCEs”).
Its proprietary BiTAC platform uses a dual-targeting, “AND-gated” architecture designed to activate therapeutic effects preferentially at tumor sites.
The company has advanced its lead BiTAC-TCE toward IND/CTA-enabling activities following cell-line development work and regulatory feedback from Germany’s Paul-Ehrlich-Institute.
VERAXA’s VXA-222 bispecific ADC has moved beyond the initial discovery phase following completion of the antibody-discovery step with OmniAb.
The company reported more than 50 granted owned or exclusively licensed patents across 26 patent families in 14 countries, alongside additional pending applications.

VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, is advancing its oncology pipeline with a strategy centered on changing how antibody-based therapies recognize and attack cancer cells. The biotechnology company is developing bispecific antibody-drug conjugates, T-cell engagers and other engineered antibody formats, with its proprietary BiTAC technology providing the distinctive element of its approach.

The latest pipeline development involves VXA-222, a bispecific antibody-drug conjugate that has moved beyond the initial discovery phase following the completion of VERAXA’s collaboration with OmniAb. VERAXA is now responsible for engineering the final therapeutic candidate using antibody binders generated through the collaboration, followed by…